Seminars in Hematology
Volume 43 , Pages S35-S43 , April 2006

The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation

  • Francine M. Foss

      Affiliations

    • Corresponding Author InformationAddress correspondence to Francine M. Foss, MD, Yale Cancer Center, Department of Medical Oncology, 333 Cedar St, New Haven, CT 06520

References 

  1. Gratwohl A , Baldomero H , Passweg J , Urbano-Ispizua A . Increasing use of reduced intensity conditioning transplants (Report of the 2001 EBMT activity survey) . Bone Marrow Transplant . 2002;30:813–831
  2. Lazarus HM , Gale RP . Blood cell and bone marrow transplants . Bone Marrow Transplant . 1996;18:839–841
  3. Giralt S , Khouri I , Champlin R . Non myeloablative “mini transplants” . Cancer Treat Res . 1999;101:97–108
  4. Champlin R , Khouri I , Shimoni A , Gajewski J , Kornblau S , Molldrem J , et al.   Harnessing graft-versus-malignancy (Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy) . Br J Haematol . 2000;111:18–29
  5. Wong R , Giralt SA , Martin T , Couriel DR , Anagnostopoulos A , Hosing C , et al.   Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years . Blood . 2003;102:3052–3059
  6. Sorror ML , Maris MB , Storer B , Sandmaier BM , Diaconescu R , Flowers C , et al.   Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning (Influence of pretransplantation comorbidities) . Blood . 2004;104:961–968
  7. Slavin S , Nagler A , Naparstek E , Kapelushnik Y , Aker M , Cividalli G , et al.   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases . Blood . 1998;91:756–763
  8. de Lima M , Anagnostopoulos A , Munsell M , Shahjahan M , Ueno N , Ippoliti C , et al.   Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome (Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation) . Blood . 2004;104:865–872
  9. Anderlini P , Saliba R , Acholonu S , Okoroji GJ , Donato M , Giralt S , et al.   Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease (Low transplant-related mortality and impact of intensity of conditioning regimen) . Bone Marrow Transplant . 2005;35:943–951
  10. Pelot MR , Pearson DA , Swenson K , Zhao G , Sachs J , Yang YG , et al.   Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen . Biol Blood Marrow Transplant . 1999;5:133–143
  11. Storb R , Raff RF , Appelbaum FR , Deeg HJ , Graham TC , Schuening FG , et al.   Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts . Blood . 1994;83:3384–3389
  12. Deeg HJ , Anasetti C , Petersdorf E , Storb R , Doney K , Hansen JA , et al.   Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors . Blood . 1994;83:3417–3418
  13. Storb R , Yu C , Wagner JL , Deeg HJ , Nash RA , Kiem HP , et al.   Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation . Blood . 1997;89:3048–3054
  14. Wagner JL , Storb R . Preclinical large animal models for hematopoietic stem cell transplantation . Curr Opin Hematol . 1996;3:410–415
  15. Yu C , Seidel K , Nash RA , Deeg HJ , Sandmaier BM , Barsoukov A , et al.   Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts . Blood . 1998;91:2581–2587
  16. Storb R , Yu C , Barnett T , Wagner JL , Deeg HJ , Nash RA , et al.   Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation . Blood . 1999;94:1131–1136
  17. Storb R , Yu C , Sandmaier B , McSweeney P , Georges G , Nash R , et al.   Mixed hematopoietic chimerism after hematopoietic stem cell allografts . Transplant Proc . 1999;31:677–678
  18. Khouri IF , Keating M , Korbling M , Przepiorka D , Anderlini P , O’Brien S , et al.   Transplant-lite (Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies) . J Clin Oncol . 1998;16:2817–2824
  19. Weisser M , Schleuning M , Ledderose G , Rolf B , Schnittger S , Schoch C , et al.   Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease . Bone Marrow Transplant . 2004;34:1083–1088
  20. Giralt S , Estey E , Albitar M , van Besien K , Rondon G , Anderlini P , et al.   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft-versus-leukemia without myeloablative therapy) . Blood . 1997;89:4531–4536
  21. Giralt S , Thall PF , Khouri I , Wang X , Braunschweig I , Ippolitti C , et al.   Melphalan and purine analog-containing preparative regimens (reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation) . Blood . 2001;97:631–637
  22. Ritchie DS , Morton J , Szer J , Roberts AW , Durrant S , Shuttleworth P , et al.   Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan . Biol Blood Marrow Transplant . 2003;9:435–442
  23. Grosskreutz C , Ross V , Scigliano E , Fruchtman S , Isola L . Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation . Biol Blood Marrow Transplant . 2003;9:453–459
  24. Childs R , Clave E , Contentin N , Jayasekera D , Hensel N , Leitman S , et al.   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (Full donor T-cell chimerism precedes alloimmune responses) . Blood . 1999;94:3234–3241
  25. Childs R , Barrett J . Nonmyeloablative stem cell transplantation for solid tumors (Expanding the application of allogeneic immunotherapy) . Semin Hematol . 2002;39:63–71
  26. Niederwieser D , Maris M , Shizuru JA , Petersdorf E , Hegenbart U , Sandmaier BM , et al.   Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases . Blood . 2003;101:1620–1629
  27. Sykes M , Preffer F , McAfee S , Saidman SL , Weymouth D , Andrews DM , et al.   Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation . Lancet . 1999;353:1755–1759
  28. Dey BR , McAfee S , Sackstein R , Colby C , Saidman S , Weymouth D , et al.   Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation . Biol Blood Marrow Transplant . 2001;7:604–612
  29. Kottaridis PD , Milligan DW , Chopra R , Chakraverty RK , Chakrabarti S , Robinson S , et al.   In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation . Blood . 2000;96:2419–2425
  30. Chakrabarti S , Mackinnon S , Chopra R , Kottaridis PD , Peggs K , O’Gorman P , et al.   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation (Potential role of Campath-1H in delaying immune reconstitution) . Blood . 2002;99:4357–4363
  31. Ho AY , Devereux S , Mufti GJ , Pagliuca A . Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions . Bone Marrow Transplant . 2003;31:551–557
  32. Faulkner RD , Craddock C , Byrne JL , Mahendra P , Haynes AP , Prentice HG , et al.   BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases (GVHD, toxicity, and survival in 65 patients) . Blood . 2004;103:428–434
  33. Ho AY , Pagliuca A , Kenyon M , Parker JE , Mijovic A , Devereux S , et al.   Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning . Blood . 2004;104:1616–1623
  34. McLaughlin P . Biotherapy for lymphoma . Curr Oncol Rep . 2000;2:157–162
  35. Major PP , Agarwal RP , Kufe DW . Clinical pharmacology of deoxycoformycin . Blood . 1981;58:91–96
  36. Mitchell BS , Sidi Y , Hershfield M , Koller CA . Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia . Ann N Y Acad Sci . 1985;451:129–137
  37. Carson DA , Kaye J , Seegmiller JE . Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine . J Immunol . 1978;121:1726–1731
  38. Steis RG , Urba WJ , Kopp WC , Alvord WG , Smith JW , Longo DL . Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients . J Natl Cancer Inst . 1991;83:1678–1679
  39. Grever MR , Siaw MF , Jacob WF , Neidhart JA , Miser JS , Coleman MS , et al.   The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy . Blood . 1981;57:406–417
  40. Foss FM . Combination therapy with purine nucleoside analogs . Oncology (Williston Park) . 2000;14:31–35
  41. Foss FM . Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma (Single-agent and combination studies) . Semin Oncol . 2000;27:58–63
  42. Miller KB , Roberts TF , Chan G , Schenkein DP , Lawrence D , Sprague K , et al.   A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease . Bone Marrow Transplant . 2004;33:881–889
  43. Miller KB , Schenkein DP , Comenzo R , Erban JK , Fogaren T , Hirsch CA , et al.   Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation . Ann Hematol . 1994;68:15–20
  44. Chan GW , Gorgun G , Miller KB , Foss FM . Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease . Biol Blood Marrow Transplant . 2003;9:170–176
  45. Pavletic SZ , Bociek RG , Foran JM , Rubocki RJ , Kuszynski CA , Wisecarver JL , et al.   Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation . Transplantation . 2003;76:877–881
  46. Sandmaier B , Maloney D , Maris M , Chauncey T , Pulsipher M , Bethge W , et al.   Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyted infusion (DLI) . Blood . 2004;103:186; (abstr)
  47. Hale G , Cobbold S , Waldmann H . T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation . Transplantation . 1988;45:753–759
  48. Martin PJ , Hansen JA , Buckner CD , Sanders JE , Deeg HJ , Stewart P , et al.   Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts . Blood . 1985;66:664–672
  49. Martin PJ , Hansen JA , Storb R , Thomas ED . T cell depletion of donor marrow for prevention of acute graft-versus-host disease . Haematol Blood Transfus . 1985;29:42–43
  50. Starobinski M , Roosnek E , Hale G , Roux E , Helg C , Chapuis B . T cell depletion of allogeneic peripheral blood stem cells . Bone Marrow Transplant . 1998;21:429–430
  51. Ho VT , Soiffer RJ . The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation . Blood . 2001;98:3192–3204
  52. Champlin RE , Passweg JR , Zhang MJ , Rowlings PA , Pelz CJ , Atkinson KA , et al.   T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings (Advantage of T-cell antibodies with narrow specificities) . Blood . 2000;95:3996–4003
  53. Breuer R , Or R , Lijovetzky G , Naparstek E , Engelhard D , Lafair J , et al.   Interstitial pneumonitis in T cell-depleted bone marrow transplantation . Bone Marrow Transplant . 1988;3:625–630
  54. Marmont AM , Horowitz MM , Gale RP , Sobocinski K , Ash RC , van Bekkum DW , et al.   T-cell depletion of HLA-identical transplants in leukemia . Blood . 1991;78:2120–2130
  55. Champlin R , Giralt S , Gajewski J . T cells, graft-versus-host disease and graft-versus-leukemia (Innovative approaches for blood and marrow transplantation) . Acta Haematol . 1996;95:157–163
  56. Auffermann-Gretzinger S , Lossos IS , Vayntrub TA , Leong W , Grumet FC , Blume KG , et al.   Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients . Blood . 2002;99:1442–1448
  57. Shlomchik WD , Couzens MS , Tang CB , McNiff J , Robert ME , Liu J , et al.   Prevention of graft versus host disease by inactivation of host antigen-presenting cells . Science . 1999;285:412–415
  58. Liu YJ , Kanzler H , Soumelis V , Gilliet M . Dendritic cell lineage, plasticity and cross-regulation . Nat Immunol . 2001;2:585–589
  59. Arpinati M , Green CL , Heimfeld S , Heuser JE , Anasetti C . Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells . Blood . 2000;95:2484–2490
  60. Waller EK , Rosenthal H , Sagar L . DC2 effect on survival following allogeneic bone marrow transplantation . Oncology (Williston Park) . 2002;16:19–26
  61. Waller EK , Rosenthal H , Jones TW , Peel J , Lonial S , Langston A , et al.   Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation . Blood . 2001;97:2948–2956
  62. Alcindor T , Gorgun G , Miller KB , Roberts TF , Sprague K , Schenkein DP , et al.   Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease . Blood . 2001;98:1622–1625

PII: S0037-1963(05)00264-7

doi: 10.1053/j.seminhematol.2005.12.007

Seminars in Hematology
Volume 43 , Pages S35-S43 , April 2006

Article Tools

* Image Usage & Resolution